HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer’s disease (AD). The newly published results of a major long-term study (J Neurol NeuroSurg Psychiatry Oct. 17, 2008) now provides powerful new evidence that taking statins substantially reduces the risk of AD.
